Integrative Approaches in Non-Small Cell Lung Cancer Management: The Role of Radiotherapy

被引:2
作者
Visa, Maxime A. [1 ]
Abazeed, Mohamed E. [2 ]
Patino, Diego Avella [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA
关键词
radiotherapy; immunotherapy; NSCLC; chemoradiotherapy; abscopal effect; STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; SURGICAL RESECTION; CLINICAL ACTIVITY; DOSE IRRADIATION; STAGE IIIA; OUTCOMES; NSCLC; TUMOR;
D O I
10.3390/jcm13154296
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Treatment guidelines for non-small cell lung cancer (NSCLC) vary by several factors including pathological stage, patient candidacy, and goal of treatment. With many therapeutics and even more combinations available in the NSCLC clinician's toolkit, a multitude of questions remain unanswered vis-a-vis treatment optimization. While some studies have begun exploring the interplay among the many pillars of NSCLC treatment-surgical resection, radiotherapy, chemotherapy, and immunotherapy-the vast number of combinations and permutations of different therapy modalities in addition to the modulation of each constituent therapy leaves much to be desired in a field that is otherwise rapidly evolving. Given NSCLC's high incidence and lethality, the experimentation of synergistic benefits that combinatorial treatment may confer presents a ripe target for advancement and increased understanding without the cost and burden of novel drug development. This review introduces, synthesizes, and compares prominent NSCLC therapies, placing emphasis on the interplay among types of therapies and the synergistic benefits some combinatorial therapies have demonstrated over the past several years.
引用
收藏
页数:17
相关论文
共 90 条
  • [1] Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis
    Abdel-Rahman, O.
    Helbling, D.
    Schmidt, J.
    Petrausch, U.
    Giryes, A.
    Mehrabi, A.
    Schoeb, O.
    Mannhart, M.
    Oweira, H.
    [J]. CLINICAL ONCOLOGY, 2017, 29 (04) : 218 - 230
  • [2] Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
    Albain, Kathy S.
    Swann, R. Suzanne
    Rusch, Valerie W.
    Turrisi, Andrew T., III
    Shepherd, Frances A.
    Smith, Colum
    Chen, Yuhchyau
    Livingston, Robert B.
    Feins, Richard H.
    Gandara, David R.
    Fry, Willard A.
    Darling, Gail
    Johnson, David H.
    Green, Mark R.
    Miller, Robert C.
    Ley, Joanne
    Sause, Willliam T.
    Cox, James D.
    [J]. LANCET, 2009, 374 (9687) : 379 - 386
  • [3] Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial
    Altorki, Nasser K.
    McGraw, Timothy E.
    Borczuk, Alain C.
    Saxena, Ashish
    Port, Jeffrey L.
    Stiles, Brendon M.
    Lee, Benjamin E.
    Sanfilippo, Nicholas J.
    Scheff, Ronald J.
    Pua, Bradley B.
    Gruden, James F.
    Christos, Paul J.
    Spinelli, Cathy
    Gakuria, Joyce
    Uppal, Manik
    Binder, Bhavneet
    Elemento, Olivier
    Ballman, Karla, V
    Formenti, Silvia C.
    [J]. LANCET ONCOLOGY, 2021, 22 (06) : 824 - 835
  • [4] American Cancer Society, Lung Cancer Statistics|How Common Is Lung Cancer?
  • [5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [6] Expanding global access to radiotherapy
    Atun, Rifat
    Jaffray, David A.
    Barton, Michael B.
    Bray, Freddie
    Baumann, Michael
    Vikram, Bhadrasain
    Hanna, Timothy P.
    Knaul, Felicia M.
    Lievens, Yolande
    Lui, Tracey Y. M.
    Milosevic, Michael
    O'Sullivan, Brian
    Rodin, Danielle L.
    Rosenblatt, Eduardo
    Van Dyk, Jacob
    Yap, Mei Ling
    Zubizarreta, Eduardo
    Gospodarowicz, Mary
    [J]. LANCET ONCOLOGY, 2015, 16 (10) : 1153 - 1186
  • [7] SANRA-a scale for the quality assessment of narrative review articles
    Baethge, Christopher
    Goldbeck-Wood, Sandra
    Mertens, Stephan
    [J]. RESEARCH INTEGRITY AND PEER REVIEW, 2019, 4 (01)
  • [8] Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma
    Barsoumian, Hampartsoum B.
    Ramapriyan, Rishab
    Younes, Ahmed, I
    Caetano, Mauricio S.
    Menon, Hari
    Comeaux, Nathan, I
    Cushman, Taylor R.
    Schoenhals, Jonathan E.
    Cadena, Alexandra P.
    Reilly, Timothy P.
    Chen, Dawei
    Masrorpour, Fatemeh
    Li, Ailin
    Hong, David S.
    Diab, Adi
    Nguyen, Quynh-Nhu
    Glitza, Isabella
    Ferrarotto, Renata
    Chun, Stephen G.
    Cortez, Maria Angelica
    Welsh, James
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [9] Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
    Berghmans, Thierry
    Durieux, Valerie
    Hendriks, Lizza E. L.
    Dingemans, Anne-Marie
    [J]. FRONTIERS IN MEDICINE, 2020, 7
  • [10] Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Bernstein, Michael B.
    Krishnan, Sunil
    Hodge, James W.
    Chang, Joe Y.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) : 516 - 524